Table 1: Scottish Medicines Consortium Advice (eye) – January 2013 through April 2014.

Medicine	SMC Drug ID	Manufacturer	Indication under review	Status	Restrictions or comments
Aflibercept (Eylea)	857/13	Bayer	Neovascular AMD	Accepted	
Aflibercept (Eylea)	954/14	Bayer	Visual impairment due to macular oedema secondary to central retinal vein occlusion	Accepted	
Bimatoprost + timolol (Ganfort Unit Dose preservative free)	906/13	Allergan	Reduction of elevated intraocular pressure (IOP) in adults with glaucoma or ocular hypertension who are insufficiently responsive to topical beta-blockers or prostaglandin analogues	Restricted	To use in patients who have proven sensitivity to preservatives
Bimatoprost 0.3mg/ml single-dose eye drops (Lumigan Unit Dose)	839/13	Allergan	Reduction of elevated IOP in chronic open-angle glaucoma or ocular hypertension in adults, as monotherapy or as adjunctive therapy to beta-blockers	Restricted	To use in patients who have proven sensitivity to the preservative benzalkonium chloride
Fluocinolone acetonide (Iluvien)	864/13	Alimera Sciences	Treatment of vision impairment associated with chronic diabetic macular oedema, considered insufficiently responsive to available therapies	Restricted	To use only in patients in whom the affected eye is pseudophakic and retreatment would take place only if the patient had previously responded to treatment with fluocinolone acetonide and subsequently best corrected visual acuity had deteriorated to less than 20/32
Latanoprost preservative-free (Monopost)	879/13	Spectrum Thea Pharmaceuticals	Reduction of elevated IOP in patients with open-angle glaucoma and ocular hypertension	Restricted	To use in patients who have proven sensitivity to the preservative benzalkonium chloride
Ocriplasmin (Jetrea)	892/13	Thrombogenics NV	Vitreomacular traction, including when associated with macular hole of diameter ≤400 microns	Not recommended	The submitting company did not present a sufficiently robust economic case to gain acceptance by SMC. The licence holder has indicated an intention to resubmit
Ranibizumab (Lucentis)	907/13	Novartis Pharmaceuticals	Visual impairment due to choroidal neovascularisation secondary to pathologic myopia	Accepted	
Ranibizumab (Lucentis)	732/11	Novartis Pharmaceuticals	This resubmission relates to branch RVO only, as the SMC previously approved the use of ranibizumab for macular oedema secondary to central RVO	Accepted	Ranibizumab was associated with significant improvements in visual acuity during six-month sham-controlled treatment in a phase III randomised double-blind study in patients with branch retinal vein occlusion. Decision May 2013 extends approved use of ranibizumab to include patients with branch retinal vein occlusion
Timolol eye gel (Tiopex) preservative free	941/14		Reduction of elevated IOP in patients with ocular hypertension or chronic open-angle glaucoma	Restricted	To use in patients who have proven sensitivity to preservatives

Across the border: Guidance issued by the Scottish Medicines Consortium is not mandatory. However, separate local NHS boards – fourteen in total – are each expected to take account of SMC guidance when making decisions about which medicines should be freely available for use, and any relevant prescribing restrictions, within NHS Scotland. The table summarises eye-related SMC appraisal advice issued in the fifteen months to April 2014.